| Firm |
Analyst |
| Benchmark |
Robert Wasserman |
| Berenberg Capital Markets |
Anita Dushyanth, Ph.D. |
| BMO Capital Markets |
Matthew Luchini |
| Canaccord Genuity |
Arlinda Lee, Ph.D. |
| Cantor |
Charles Duncan, Ph.D. |
| Evercore ISI |
Michael DiFiore, Pharm.D., MBA |
| Goldman Sachs |
Graig C. Suvannavejh, Ph.D. |
| Jefferies & Company |
Eun K. Yang, Ph.D. |
| JMP Securities |
Jason N. Butler, Ph.D. |
| JP Morgan |
Jessica Fye |
| Piper Sandler |
Joseph Catanzaro |
| SVB Leerink |
Geoffrey C. Porges MBBS |
| Wells Fargo |
Nick Abbott, Ph.D. |
Halozyme Therapeutics, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Halozyme Therapeutics, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Halozyme Therapeutics, Inc. or its management. Halozyme Therapeutics, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.